U.S. markets closed

Enanta Pharmaceuticals, Inc. (ENTA)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
48.20-1.31 (-2.65%)
At close: 4:00PM EDT
48.20 0.00 (0.00%)
After hours: 12:00AM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Momentum

Momentum

Previous Close49.51
Open49.48
Bid48.03 x 800
Ask54.00 x 1000
Day's Range48.16 - 50.70
52 Week Range40.32 - 56.97
Volume102,789
Avg. Volume134,291
Market Cap973.404M
Beta (5Y Monthly)0.40
PE Ratio (TTM)N/A
EPS (TTM)-3.68
Earnings DateAug 05, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est68.14
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Enanta Pharmaceuticals to Present at the RBC Capital Markets Global Healthcare Conference
    Business Wire

    Enanta Pharmaceuticals to Present at the RBC Capital Markets Global Healthcare Conference

    Enanta Pharmaceuticals to Present at the RBC Capital Markets Global Healthcare Conference.

  • Enanta's EDP-514 Four-Week Treatment Shows Around 10 Time Reduction In Hepatitis B Virus RNA
    Benzinga

    Enanta's EDP-514 Four-Week Treatment Shows Around 10 Time Reduction In Hepatitis B Virus RNA

    Enanta Pharmaceuticals Inc (NASDAQ: ENTA) has announced data from the first two dose cohorts of Part 2 of its Phase 1b study evaluating EDP-514 in chronic hepatitis B virus (HBV) patients already being treated with a nucleoside reverse transcriptase inhibitor (NUC). The data demonstrated that EDP-514, the Company's novel class II oral HBV core inhibitor, was safe and well-tolerated, displayed pharmacokinetics (PK) supportive of once-daily dosing, and resulted in a mean reduction in HBV RNA of 1 log. A mean reduction in HBV RNA of 1 log (10 times) was observed in patients dosed with EDP-514 compared to 0.3 log (2 times) in the placebo group after 28 days of treatment, similar to reported results for other HBV core inhibitors. A maximum reduction of 2.3 log (HBeAg-negative) and 2.8 log (HBeAg-positive) was observed in patients receiving EDP-514 compared with a maximum 1.2 log reduction in those receiving placebo. The HBV DNA assessment did not show any change from baseline as these patients already had suppressed HBV DNA levels from NUC therapy. Additionally, no virologic failure or breakthrough was observed, and as expected, there were no changes in HBsAg, HBeAg, or HBcrAg levels. EDP-514 was safe and well-tolerated, and pharmacokinetics were supportive of once-daily dosing. EDP-514 exposure increased linearly with dose, achieving trough concentrations up to 18-fold the protein-adjusted EC50. No liver enzyme elevations or other laboratory abnormalities were reported, and no serious adverse events occurred during the treatment period and the 4-week follow-up. Price Action: ENTA shares are trading lower by 2.98% at $49.47 on the last check Friday. See more from BenzingaClick here for options trades from BenzingaiBio Stock Is Trading Higher After Announcing Next-Gen COVID-19 Vaccine CandidateCorcept Stops Phase 2 NASH Study With Miricorilant Due To Elevated Liver Enzymes In Patients© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • Enanta Pharmaceuticals Inc (ENTA) Q2 2021 Earnings Call Transcript
    Motley Fool

    Enanta Pharmaceuticals Inc (ENTA) Q2 2021 Earnings Call Transcript

    On the call today is Dr. Jay Luly, President and Chief Executive Officer; Paul Mellett, our Chief Financial Officer; and other members of Enanta's senior management team. Thank you, Jennifer, and good afternoon, everyone.